http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112426432-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2020-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112426432-B |
| titleOfInvention | Composition of paris polyphylla saponin VII and multiple myeloma clinical medicine and application thereof |
| abstract | The invention discloses a composition of paris polyphylla saponin VII and a clinical medicine for multiple myeloma and application thereof. Compared with the single clinical medicine of the paris saponin VII or multiple myeloma, the invention adopts the combination of the paris saponin VII and the bortezomib or the paris saponin VII and the adriamycin, and has better function of inhibiting cell proliferation. The composition greatly improves the sensitivity of multiple myeloma cells to bortezomib or adriamycin, and is particularly suitable for treating relapsed/refractory multiple myeloma patients. |
| priorityDate | 2020-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.